Income statement
AUD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2M | 2M | 2M | 8M | 2M |
| Gross Profit | 2M | 2M | 1M | 7M | 1M |
| Operating Income | -8M | -9M | -13M | -4M | -6M |
| EBITDA | -9M | -10M | -16M | -14M | -9M |
| Net Income | -9M | -10M | -14M | -5M | -8M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.009
+0.00% today
1Y Change
+178.13%
Window
Jun 27, 2025 → Jun 18, 2026
Coverage: 252 bars · Jun 27, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Cynata Therapeutics Ltd. (CYYNF) is a Healthcare stock with a market cap of $70.00M and listed on OTC. The stock last traded around $0.01 and up 178.1% across the available one-year price window (Jun 27, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -18.6%, EPS growth of +15.5%, a dividend yield of 0.0%. What stands out right now is revenue -18.6%, EPS +15.5%, free cash flow +11.9% with operating margin 16974.1% and ROIC -353.7%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CYYNF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CYYNF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CYYNF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CYYNF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.5M
-80.1% YoY
FY Net Income
-$7.7M
-41.2% YoY
Free Cash Flow
-$5.2M
-56.5% YoY
Revenue Growth
-18.6%
EPS Growth
+15.5%
Gross Margin
253.3%
Net Margin
9887.9%
Income statement
AUD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2M | 2M | 2M | 8M | 2M |
| Gross Profit | 2M | 2M | 1M | 7M | 1M |
| Operating Income | -8M | -9M | -13M | -4M | -6M |
| EBITDA | -9M | -10M | -16M | -14M | -9M |
| Net Income | -9M | -10M | -14M | -5M | -8M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
AUD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 5M | 6M | 16M | 24M | 27M |
| Total Assets | 7M | 8M | 19M | 27M | 30M |
| Total Liabilities | 1M | 1M | 2M | 3M | 2M |
| Shareholder Equity | 6M | 7M | 17M | 24M | 28M |
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -5M | -6M | -16M | -24M | -27M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
5M
-56.5% YoY
Capital Expenditures
0
Free Cash Flow
5M
-56.5% YoY
Key ratios
Gross Margin
253.3%
Operating Margin
16974.1%
Net Margin
9887.9%
ROE
-179.4%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.